

June 2018—Gordon Dunn Report

1. *Use of Prostate Specific Membrane Antigen together with PET/CT Scan*

Title: Outcome after PSMA PET/CT based radiotherapy in patients with biochemical cancer persistence or recurrence after radical prostatectomy:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833127/>

This technology is used for identifying soft tissue tumours such as in lymph nodes. PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared to conventional imaging and results in a change of treatment in a remarkably high number of patients.

Currently, there is a BC Cancer trial in progress as well. The purpose of this study (at BC Cancer) is to compare the accuracy, sensitivity and specificity of 18F-NaF imaging to 99mTc-MDP bone SPECT imaging for bone metastasis detection. As well as evaluate the short-term undesirable side effects.

2. *Use of PSMA/PET-CT Scan with Lutetium 177. Currently, Lu-177 with PSMA-617 has been found to be highly promising for treatment of advanced stage prostate cancer in clinical trial.*

Title: Clinical trial finds strong promise for new treatment that targets radiation directly to prostate cancer

<https://www.pcf.org/news/clinical-trial-finds-strong-promise-new-treatment-targets-radiation-directly-prostate-cancer/>

3. *Updated Prostate Cancer Screening Guidelines*

Title: Prostate Cancer Foundation Statement on U.S. Preventive Services Task Force Prostate Screening Guidelines

<https://www.pcf.org/news/pcf-statement-on-2018-uspstf-final-recommendation-on-prostate-cancer-screening/>

4. **Title: Why Cleveland Clinic, Kaiser are touting group appointments for patients with prostate cancer instead of one on one appointments with urologist or oncologist.**

<https://www.beckershospitalreview.com/quality/why-cleveland-clinic-kaiser-are-touting-group-appointments-for-patients.html>